Departments of Anesthesiology and Pharmacology & Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA.
Neuropsychopharmacology. 2010 Mar;35(4):999-1007. doi: 10.1038/npp.2009.203. Epub 2009 Dec 23.
Muscimol has been regarded as a universal agonist for all gamma-aminobutyric acid type A receptor (GABA(A)-R) subtypes. However, brain regional distribution of muscimol's high-affinity binding sites greatly differs from those of other binding sites of the GABA(A)-R. To test whether behavioral effects of muscimol correlated with the density of high-affinity [(3)H]muscimol binding, we examined several GABA(A)-R subunit gene-modified mouse lines: alpha1, alpha4, or delta-knockouts (KO), alpha4+delta-double KO, and Thy1.2 promoter-driven alpha6 transgenic mice (Thy1alpha6). We determined the high-affinity [(3)H]muscimol binding in brain sections by quantitative autoradiography and sedative/ataxic effects induced in vivo by muscimol using a constant speed rotarod. alpha4-KO mice had reduced [(3)H]muscimol binding in the caudate-putamen, thalamus, and hippocampus, and were less sensitive to the behavioral impairment by muscimol. Similarly, delta-KO mice also had reduced binding to forebrain regions and a lower behavioral sensitivity to muscimol than their wild-type controls. In contrast, alpha1-KO mice had unaltered behavioral sensitivity to muscimol and unaltered [(3)H]muscimol binding, even though previous studies have demonstrated dramatically reduced binding to various other GABA(A)-R sites in these mice. Finally, Thy1alpha6 mice exhibited increased behavioral sensitivity to muscimol, and to another direct GABA-site agonist gaboxadol, and increased [(3)H]muscimol binding in the cerebral cortex and hippocampus. Thus, the differences in sedative and motor-impairing actions of muscimol in various mouse models correlated with the level of forebrain high-affinity [(3)H]muscimol binding. These data suggest that a small special population of GABA(A)-Rs, most likely extrasynaptic non-alpha1-containing receptors, strongly contributes to the in vivo pharmacological effects of muscimol.
麦司卡林被认为是所有γ-氨基丁酸 A 型受体(GABA(A)-R)亚型的通用激动剂。然而,脑内麦司卡林高亲和力结合位点的区域分布与 GABA(A)-R 的其他结合位点有很大的不同。为了测试麦司卡林的行为效应是否与高亲和力[3H]麦司卡林结合的密度相关,我们研究了几种 GABA(A)-R 亚基基因修饰的小鼠品系:α1、α4 或 δ 敲除(KO)、α4+δ 双 KO 和 Thy1.2 启动子驱动的α6 转基因(Thy1α6)小鼠。我们通过定量放射自显影测定脑切片中的高亲和力[3H]麦司卡林结合,并通过恒速转棒测定体内麦司卡林诱导的镇静/共济失调效应。α4-KO 小鼠在尾壳核、丘脑和海马体中的[3H]麦司卡林结合减少,对麦司卡林引起的行为障碍的敏感性降低。同样,δ-KO 小鼠在前脑区域的结合也减少,对麦司卡林的行为敏感性也低于其野生型对照。相比之下,α1-KO 小鼠对麦司卡林的行为敏感性和[3H]麦司卡林结合没有改变,尽管之前的研究表明这些小鼠对其他各种 GABA(A)-R 位点的结合显著减少。最后,Thy1α6 小鼠对麦司卡林和另一种直接 GABA 位点激动剂 gaboxadol 的行为敏感性增加,并且在大脑皮层和海马体中的[3H]麦司卡林结合增加。因此,各种小鼠模型中麦司卡林的镇静和运动损伤作用的差异与前脑高亲和力[3H]麦司卡林结合的水平相关。这些数据表明,一小部分特殊的 GABA(A)-R,很可能是 extrasynaptic 非α1 包含的受体,强烈促成了麦司卡林在体内的药理学效应。